Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Apr 8;4(4):CD004762.
doi: 10.1002/14651858.CD004762.pub3.

Drug treatment for myotonia

Jennifer Spillane  1 , Jeroen Trip  2 , Gea Drost  3 , Catharina G Faber  4 , Michael G Hanna  1   5 , Sarah J Nevitt  6   7 , Vinojini Vivekanandam  1   5
Affiliations
Meta-Analysis

Drug treatment for myotonia

Jennifer Spillane et al. Cochrane Database Syst Rev. .

Abstract

Background: Abnormal delayed relaxation of skeletal muscles, known as myotonia, can cause disability in myotonic disorders. The main myotonic disorders are non-dystrophic myotonia and myotonic dystrophy. Non-dystrophic myotonia is a genetic muscle channelopathy predominantly causing myotonia. Myotonic dystrophic is a more systemic neuromuscular disorder causing myotonia as well as progressive myopathy and systemic manifestations, such as arrhythmias and cataracts. Myotonia manifests as stiffness, cramps, locking, pain, and fatigue, and can cause marked morbidity and disability. Sodium channel blockers, tricyclic antidepressive drugs, benzodiazepines, calcium antagonists, taurine, and prednisone may reduce myotonia. This is an update of a review first published in 2005 and updated in 2006.

Objectives: To review evidence from randomised controlled trials (RCTs) on the efficacy and tolerability of drug treatment in people with clinical myotonia due to myotonic disorders.

Search methods: We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and World Health Organization ICTRP on 29 March 2023. We handsearched the grey literature and contacted disease experts and antimyotonic drug manufacturers.

Selection criteria: We included RCTs involving participants with myotonia treated with any drug treatment versus no therapy, placebo, or any other active drug treatment. We included clinical trials where the reported primary outcome was a participant-reported measure of myotonia. We excluded non-RCTs and where myotonia may have been part of the condition (e.g. paramyotonia or Brody's disease). The primary myotonic conditions were myotonic dystrophy and non-dystrophic myotonia. Our primary outcome was participant-reported improvement in clinical myotonia. Our secondary outcomes were relaxation time, electromyographic relaxation time, adverse events, and quality of life.

Data collection and analysis: Review authors independently extracted the data onto standardised extraction forms. Three review authors independently assessed risk of bias and we collected adverse events data from the included trials. We assessed the certainty of the evidence using GRADE.

Main results: This review includes 17 double-blind or single-blind RCTs involving a total of 392 participants, 219 with myotonic dystrophy type 1 and 173 with non-dystrophic myotonia. Seven RCTs were newly identified and included in this update. Four of these RCTs investigated the effect of mexiletine or lamotrigine versus placebo in people with non-dystrophic myotonia. The remaining RCTs explored mexiletine in myotonic dystrophy. Myotonic dystrophy Mexiletine No RCTs reported improvement in clinical myotonia according to validated scales. Mexiletine likely reduces hand grip relaxation time compared to placebo (mean difference (MD) 1.37 seconds better, 95% confidence interval (CI) 0.87 to 1.86; 2 RCTs, 56 participants; moderate-certainty evidence). Low-certainty evidence from four RCTs (91 participants) reported 55 adverse events with placebo and 84 adverse events with mexiletine. The most frequent adverse events with mexiletine were gastrointestinal symptoms, lethargy, and headache. There may be no difference in quality of life measures between mexiletine and placebo (36-item Short Form (SF-36) Physical Component Summary (PCS): MD -1.40, 95% CI -5.56 to 2.76; SF-36 Mental Component Summary (MCS): MD -1.10, 95% CI -6.17 to 3.97; 1 RCT, 38 participants; low-certainty evidence). Non-dystrophic myotonia Mexiletine Mexiletine likely reduces myotonia compared to placebo using the Interactive Voice Response Diary Stiffness score (across both treatment periods: MD -3.12, 95% CI -3.75 to -2.49; 2 cross-over RCTs, 89 participants; moderate-certainty evidence). There is likely no effect on relaxation times with no differences in eye closure or clinical hand grip between mexiletine and placebo (2 RCTs, 89 participants; moderate-certainty evidence). Mexiletine likely improves quantitative hand grip (MD -0.11, 95% CI -0.18 to -0.04; 2 RCTs, 89 participants; moderate-certainty evidence). Mexiletine likely improves electromyographic-based outcomes, including degree of needle electromyographic myotonia detected (MD -0.67, 95% CI -0.23 to -1.11; 2 RCTs, 89 participants; moderate-certainty evidence). Low-certainty evidence from four RCTs (136 participants) reported 29 adverse events with placebo and 94 adverse events with mexiletine. The most frequent adverse events were gastrointestinal symptoms, lethargy, and headache. There may be improvement in quality of life with mexiletine compared to placebo (SF-36 PCS: MD 6.45, 95% CI 4.32 to 8.58; SF-36 MCS: MD 6.78, 95% CI 1.89 to 11.67, entire treatment period; 2 cross-over RCTs, 89 participants; low-certainty evidence). Lamotrigine No RCTs reported improvement in clinical myotonia according to validated scales. There may be improvement in relaxation time with lamotrigine treatment (hand grip: MD 2.80 (log) seconds better, 95% CI 2.09 to 3.51; eyelid closure: MD 2.30 (log) seconds better, 95% CI 1.79 to 2.81; 1 RCT, 22 participants; low-certainty evidence). Moderate-certainty evidence from one RCT (26 participants) reported 23 adverse events with placebo and 44 adverse events with lamotrigine. The most common adverse events with lamotrigine were headache, fatigue, and rash. Quality of life is likely to improve with lamotrigine compared to placebo (SF-36: MD 5.00 points better, 95% CI 3.12 to 6.88 points better; 1 RCT, 22 participants; moderate-certainty evidence). Other medications Other medications, including phenytoin, imipramine, procainamide, clomipramine, nifedipine, tocainide, diazepam, quinine, diphenylhydantoin, and taurine, were either ineffective or had uncertain evidence with small numbers. Trials were small, with the participant numbers ranging from nine to 59, with high risk of bias.

Authors' conclusions: More-recent trials are more robust, and well-conducted RCTs demonstrate moderate-certainty evidence for the efficacy of symptomatic treatments in non-dystrophic myotonias. Additionally, the data suggest that not all patients respond to therapy and research into aetiology and treatment options for non-responders is needed. Other agents that have not been tested in RCTs, such as acetazolamide, flecainide, ranolazine, and lacosamide, will need to be considered when planning future clinical trials. Moreover, the RCTs, in particular the small numbers of most trials, highlight the challenges in recruitment and design of robust trials in rare diseases, and research into trial design to improve recruitment in rare diseases will be important for future trials.

Trial registration: ClinicalTrials.gov NCT02251457.

PubMed Disclaimer

Conflict of interest statement

VV: declared involvement in an eligible study, as chief investigator of MEND (MExiletine versus lamotrigine in Non‐Dystrophic myotonia) (NCT05017155), grant and charity funded. VV was not involved in eligibility decisions, data extraction, risk of bias, or GRADE assessments for this study.

JS: UCB UK (Travel), argenx (Independent Contractor – Consultant), UCB UK (Independent Contractor – Consultant), argenx (Travel).

JT: none.

GD: none.

CGF: Maastricht Universitair Medisch Centrum (Employment), OliPass (Independent Contractor – Consultant), Sangamo (Independent Contractor – Consultant).

MGH: declared involvement in eligible studies, Statland 2012 and NCT05017155, funded by Neuromuscular Study Group, Jon Moulton Charity Trust, UCLH BRC Fast Track Grant. MGH was not involved in eligibility decisions, data extraction, risk of bias, or GRADE assessments for these studies.

SN: Statistical Editor of the Cochrane Neuromuscular Group up to March 2023. SN was not involved in the editorial process of this review.

Update of

References

References to studies included in this review

Andersen 2017 {published data only}
    1. Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain 2017;140(9):2295-305. [DOI: ] - PubMed
Antonini 1990 {published data only}
    1. Antonini G, Vichi R, Leardi MG, Pennisi E, Monza GC, Millefiorini M. Effect of clomipramine on myotonia: a placebo-controlled, double-blind, crossover trial. Neurology 1990;40(9):1473-4. [PMID: ] - PubMed
Bassez 2018 {published data only}
    1. Bassez G, Audureau E, Hogrel JY, Arrouasse RI, Baghdoyan S, Bhugaloo H, et al. Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial. Brain 2018;141(10):2855-65. [DOI: 10.1093/brain/awy231] - DOI - PubMed
Durelli 1983 {published data only}
    1. Durelli L, Mutani R, Fassio F. The treatment of myotonia: evaluation of chronic oral taurine therapy. Neurology 1983;33(5):599-603. [PMID: ] - PubMed
Finlay 1982 {published data only}
    1. Finlay M. A comparative study of disopyramide and procainamide in the treatment of myotonia in myotonic dystrophy. Journal of Neurology, Neurosurgery, and Psychiatry 1982;45(5):461-3. [PMID: ] - PMC - PubMed
Gascon 1989 {published data only}
    1. Gascon GG, Staton RD, Patterson BD, Konewko PJ, Wilson H, Carlson KM, et al. A pilot controlled study of the use of imipramine to reduce myotonia. American Journal of Physical Medicine & Rehabilitation 1989;68(5):215-20. [PMID: ] - PubMed
Grant 1987 {published data only}
    1. Grant R, Sutton DL, Behan PO, Ballantyne JP. Nifedipine in the treatment of myotonia in myotonic dystrophy. Journal of Neurology, Neurosurgery, and Psychiatry 1987;50(2):199-206. [PMID: ] - PMC - PubMed
Heatwole 2021 {published data only}
    1. Heatwole C, Luebbe E, Rosero S, Eichinger K, Martens W, Hilbert J, et al. Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial. Neurology 2021;96(2):e228-40. [CLINICALTRIALS.GOV: ClinicalTrials.gov Identifier: NCT01406873] - PMC - PubMed
Kratz 1986 {published data only}
    1. Kratz R, Hawley RJ, Jackson LK, Gheen I. Treatment of myotonia with mexiletine. Muscle & Nerve (Abstract) 1986;9(Suppl 5):199.
Kwiecinski 1992 {published data only}
    1. Kwiecinski H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurologica Scandinavica 1992;86(4):371-5. [PMID: ] - PubMed
Lewis 1966 {published data only}
    1. Lewis I. Trial of diazepam in myotonia – a controlled clinical trial. Neurology 1966;16(8):831-6.
Leyburn 1959 {published data only}
    1. Leyburn P, Walton JN. The treatment of myotonia: a controlled clinical trial. Brain 1959;82(1):81-91. [PMID: ] - PubMed
Logigian 2010a {published data only}
    1. Logigian EL, Martens WB, Moxley RT 4th, McDermott MP, Dilek N, Wiegner AW, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010;74(18):1441-8. [PMID: ] - PMC - PubMed
Logigian 2010b {published data only}
    1. Logigian EL, Martens WB, Moxley RT 4th, McDermott MP, Dilek N, Wiegner AW, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010;74(18):1441-8. [PMID: ] - PMC - PubMed
Munsat 1967 {published data only}
    1. Munsat TL. Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide, and placebo. Neurology 1967;17(4):359-67. [PMID: ] - PubMed
Statland 2012 {published data only}
    1. Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 2012;308(13):1357-65. [DOI: 10.1001/jama.2012.12607] [PMID: ] - DOI - PMC - PubMed
Stunnenberg 2018 {published data only}
    1. Stunnenberg BC, Raaphorst J, Groenewoud HM, Statland JM, Griggs RC, Woertman W, et al. Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA 2018;320(22):2344-53. [CLINICALTRIALS.GOV: NCT02045667] - PMC - PubMed
Vicart 2021 {published data only}
    1. Vicart S, Franques J, Bouhour F, Magot A, Péréon Y, Sacconi S, et al. Efficacy and safety of mexiletine in non-dystrophic myotonias: a randomised, double-blind, placebo-controlled, cross-over study. Neuromuscular Disorders 2021;31(11):1124-35. [CT.GOV: NCT02336477] - PubMed

References to studies excluded from this review

Alfonsi 2007 {published data only}
    1. Alfonsi E, Merlo IM, Tonini M, Ravaglia S, Brugnoni R, Gozzini A, et al. Efficacy of propafenone in paramyotonia congenita. Neurology 2007;68(13):1080. - PubMed
Arnold 2017 {published data only}
    1. Arnold WD, Kline D, Sanderson A, Hawash AA, Bartlett A, Novak KR, et al. Open-label trial of ranolazine for the treatment of myotonia congenita. Neurology 2017;89(7):710-3. - PMC - PubMed
Backman 1990 {published data only}
    1. Backman E, Henriksson KG. Effect of sodium selenite and vitamin E treatment in myotonic dystrophy. Journal of Internal Medicine 1990;228(6):577-81. - PubMed
Benstead 1987 {published data only}
    1. Benstead TJ, Camfield PR, King DB. Treatment of paramyotonia congenita with acetazolamide. Canadian Journal of Neurological Sciences 1987;14(2):156-8. - PubMed
Birnberger 1975 {published data only}
    1. Birnberger KL, Rudel R, Struppler A. Clinical and electrophysiological observations in patients with myotonic muscle disease and the therapeutic effect of N-propyl-ajmalin. Journal of Neurology 1975;210(2):99-110. - PubMed
Brumback 1983 {published data only}
    1. Brumback RA, Carlson KM. The depression of myotonic dystrophy: response to imipramine. Journal of Neurology, Neurosurgery, and Psychiatry 1983;46(6):587-8. - PMC - PubMed
Chisari 2009 {published data only}
    1. Chisari C, Licitra R, Pellegrini M, Pellegrino M, Rossi B. Fluoxetine blocks myotonic runs and reverts abnormal surface electromyogram pattern in patients with myotonic dystrophy type 1. Clinical Neuropharmacology 2009;32(6):330-4. - PubMed
Cook 1984 {published data only}
    1. Cook JD, Henderson-Tilton AC. Beneficial response to a calcium channel antagonist in myotonic syndromes. Neurology 1984;34(Suppl 1):193-4.
Durelli 1982 {published data only}
    1. Durelli L, Mutani R, Fassio F, Satta A, Bartoli E. Taurine and hyperexcitable human muscle: effects of taurine on potassium-induced hyperexcitability of dystrophic myotonic and normal muscles. Annals of Neurology 1982;11(3):258-65. - PubMed
Garai 1954 {published data only}
    1. Garai O. The treatment of dystrophia myotonica with A.C.T.H. Journal of Neurology, Neurosurgery and Psychiatry 1954;17(1):83-6. - PMC - PubMed
Geschwind 1955 {published data only}
    1. Geschwind N, Simpson JA. Procaine amide in the treatment of myotonia. Brain 1955;78(1):81-91. - PubMed
Griggs 1977 {published data only}
    1. Griggs RC, Moxley RT 3rd, Riggs JE, Engel WK. Effect of acetazolamide on myotonia. Transactions of the American Neurological Association 1977;102:133-5. - PubMed
Griggs 1978 {published data only}
    1. Griggs RC, Moxley RT 3rd, Riggs RE, Engel WK. Effects of acetazolamide on myotonia. Annals of Neurology 1978;3(6):531-7. - PubMed
Griggs 1989 {published data only}
    1. Griggs RC, Pandya S, Florence JM, Brooke MH, Kingston W, Miller JP, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 1989;39(2 Pt 1):219-22. - PubMed
Guilleminault 1978 {published data only}
    1. Guilleminault C, Flagg WH, Coburn SC, Dement WC. Baclofen trial in six myotonic dystrophy patients. Acta Neurologica Scandinavica 1978;57(3):232-8. - PubMed
Heatwole 2011 {published data only}
    1. Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, et al. Open-label trial of recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Archives of Neurology 2011;68(1):37-44. - PMC - PubMed
Hughes 1991 {published data only}
    1. Hughes EF, Wilson J. Response to treatment with antihistamines in a family with myotonia congenita. Lancet 1991;337(8732):28-30. - PubMed
Jackson 1994 {published data only}
    1. Jackson CE, Barohn RJ, Ptacek LJ. Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy. Muscle and Nerve 1994;17(7):763-8. - PubMed
Karli 1974 {published data only}
    1. Karli P, Bergstrom L. Effect of baclofen on myotonia. Lancet 1974;1(7869):1285-6. - PubMed
Lorusso 2019 {published data only}
    1. Lorusso S, Kline D, Bartlett A, Freimer M, Agriesti J, Hawash AA, et al. Open-label trial of ranolazine for the treatment of paramyotonia congenita. Muscle & Nerve 2019;59(2):240-3. - PMC - PubMed
Matsumura 2004 {published data only}
    1. Matsumura T, Yokoe M, Nakamori M, Hattori N, Saito T, Nozaki S, et al. A clinical trial of creatine monohydrate in muscular dystrophy patients. Clinical Neurology 2004;44(10):661-6. - PubMed
Mielke 1985 {published data only}
    1. Mielke U, Haass A, Sen S, Schmidt W. Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert. Journal of Neurology 1985;232(5):271-4. - PubMed
Milner‐Brown 1990 {published data only}
    1. Milner-Brown HS, Miller RG. Myotonic dystrophy: quantification of muscle weakness and myotonia and the effect of amitriptyline and exercise. Archives of Physical Medicine and Rehabilitation 1990;71(12):983-7. - PubMed
Müller 1980 {published data only}
    1. Müller D, Leuschner U. Clinical and neurophysiological findings in serum controlled diphenylhydantoin application – considerations on myotonic dystrophy therapy [Klinische und neurophysiologische befunde bei blutspiegelkontrollierter diphenylhydantoinapplikation – überlegung zur therapie der myotonen dystrophie]. Psychiatrie, Neurologie, und medizinische Psychologie 1980;32(8):464-8. - PubMed
Orndahl 1986 {published data only}
    1. Orndahl G, Sellden U, Hallin S, Wetterqvist H, Rindby A, Selin E. Myotonic dystrophy treated with selenium and vitamin E. Acta Medica Scandinavica 1986;219(4):407-14. - PubMed
Orndahl 1994 {published data only}
    1. Orndahl G, Grimby G, Grimby A, Johansson G, Wilhelmsen L. Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study. Journal of Internal Medicine 1994;235(3):205-10. - PubMed
Pendefunda 1974 {published data only}
    1. Pendefunda GH, Stefanache F, Cozma V. The treatment of myotonia with L-Dopa. Clinical and electromyographic study. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi 1974;78(3):591-602. - PubMed
Pénisson‐Besnier 2008 {published data only}
    1. Pénisson-Besnier I, Devillers M, Porcher R, Orlikowski D, Doppler V, Desnuelle C, et al. Dehydroepiandrosterone for myotonic dystrophy type 1. Neurology 2008;71(6):407-12. - PubMed
Ricker 1980 {published data only}
    1. Ricker K, Haass A, Rudel R, Bohlen R, Mertens HG. Successful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide. Journal of Neurology, Neurosurgery, and Psychiatry 1980;43(3):268-71. - PMC - PubMed
Rüdel 1980 {published data only}
    1. Rüdel R, Dengler R, Ricker K, Haass A, Emser W. Improved therapy of myotonia with the lidocaine derivative tocainide. Journal of Neurology 1980;222(4):275-8. - PubMed
Samaha 1964 {published data only}
    1. Samaha FJ. Von Eulenberg's paramyotonia. A clinical study of restricted myotonia and episodic paralysis successfully controlled by chlorothiazide. Transactions of the American Neurological Association 1964;89:87-91. - PubMed
Schneider‐Gold 2003 {published data only}
    1. Schneider-Gold C, Beck M, Wessig C, George A, Kele H, Reiners K, et al. Creatine monohydrate in DM2/PROMM: a double-blind placebo controlled clinical study. Proximal myotonic myopathy. Neurology 2003;60(3):500-2. - PubMed
Sechi 1983 {published data only}
    1. Sechi GP, Traccis S, Durelli L, Monaco F, Mutani R. Carbamazepine versus diphenylhydantoin in the treatment of myotonia. European Neurology 1983;22(2):113-8. - PubMed
Streib 1987 {published data only}
    1. Streib EW. Paramyotonia congenita: successful treatment with tocainide. Clinical and electrophysiologic findings in seven patients. Muscle & Nerve 1987;10(2):155-62. - PubMed
Sugino 1998 {published data only}
    1. Sugino M, Ohsawa N, Ito T, Ishida S, Yamasaki H, Kimura F, et al. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 1998;51(2):586-9. - PubMed
Tarnopolsky 2004 {published data only}
    1. Tarnopolsky M, Mahoney D, Thompson T, Naylor H, Doherty TJ. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle & Nerve 2004;29(1):51-8. - PubMed
Vlachopapadopoulou 1995 {published data only}
    1. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, Manzione D, Bier DM, Matthews DE, et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy – a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1995;80(12):3715-23. - PubMed
Walter 2002 {published data only}
    1. Walter MC, Reilich P, Lochmuller H, Kohnen R, Schlotter B, Hautmann H, et al. Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. Journal of Neurology 2002;249(12):1717-22. - PubMed

References to ongoing studies

NCT03692312 {published data only}
    1. NCT03692312. Efficacy and safety of tideglusib in congenital myotonic dystrophy [A randomized, double-blind study to evaluate the efficacy and safety of tideglusib versus placebo for the treatment of children and adolescents with congenital myotonic dystrophy (REACH CDM)]. https://clinicaltrials.gov/study/NCT03692312 (first posted 2 October 2018).
NCT04622553 {unpublished data only}
    1. NCT04622553. Open-label extension study in paediatric patients who have completed the MEX-NM-301 study [Open-label extension study to evaluate the long-term safety and efficacy of mexiletine in paediatric patients with myotonic disorders who have completed the MEX-NM-301 study]. https://clinicaltrials.gov/study/NCT04622553 (first posted 10 November 2020).
NCT04624750 {unpublished data only}
    1. NCT04624750. Open label study in adolescents and children with myotonic disorders [An open-label, non-comparative study to evaluate the steady-state pharmacokinetics, safety, and efficacy of mexiletine in adolescents and children with myotonic disorders]. https://clinicaltrials.gov/study/NCT04624750 (first posted 12 November 2020).
NCT05017155 {published data only}
    1. NCT05017155. MExiletine versus lamotrigine in Non-Dystrophic myotonia (MEND) [A phase III, randomised, double blinded, head-to-head, single-site, cross-over trial of lamotrigine versus mexiletine for non-dystrophic myotonias]. https://clinicaltrials.gov/study/NCT05017155 (first posted 23 August 2021).
NCT05639257 {unpublished data only}
    1. NCT05639257. Treatment of myotonia – lamotrigine versus namuscla. https://clinicaltrials.gov/study/NCT05639257 (first posted 6 December 2022).

Additional references

Altamura 2023
    1. Altamura C, Saltarella I, Campanale C, Laghetti P, Desaphy JF. Drug repurposing in skeletal muscle ion channelopathies. Current Opinion in Pharmacology 2023;68:102329. [DOI: 10.1016/j.coph.2022.102329] - DOI - PubMed
Armitage 1987
    1. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford (UK): Blackwell Scientific Publication, 1987.
Baumann 1998
    1. Baumann P, Myllyla R, Leisti J. Myotonia congenita in northern Finland: an epidemiological and genetic study. Journal of Medical Genetics 1998;35(4):293-6. - PMC - PubMed
Becker 1970
    1. Becker PE. Paramyotonia Congenita (Eulenburg). Stuttgart (Germany): George Thieme Verlag, 1970.
Becker 1977
    1. Becker PE, Knussmann R, Kuhn E. Myotonia Congenita and Syndromes Associated with Myotonia. Clinical-Genetic Studies of the Nondystrophic Myotonias. Stuttgart (Germany): George Thieme Publishers, 1977.
Bernareggi 2005
    1. Bernareggi A, Furling D, Mouly V, Ruzzier F, Sciancalepore M. Myocytes from congenital myotonic dystrophy display abnormal Na+ channel activities. Muscle & Nerve 2005;31(4):506-9. - PubMed
Bourin 2009
    1. Bourin M, Chenu F, Hascoët M. The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers. Current Drug Targets 2009;10:1052-60. [DOI: 10.2174/138945009789735138] - DOI - PubMed
Bowman 1981
    1. Bowman WC. Effects of adrenergic activators and inhibitors on the skeletal muscles. In: Szekeres L, editors(s). Handbook of Experimental Pharmacology: Adrenergic Activators and Inhibitors, Part II. Vol. 54/II. Berlin (Germany): Springer-Verlag, 1981:47-128.
Breslow 1980
    1. Breslow NE, Day NE. Statistical Methods in Cancer Research: the Analysis of Case-Control Studies. Vol. I. Lyon (France): International Agency for Research in Cancer, 1980. - PubMed
Brook 1992
    1. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992;69(2):385. - PubMed
Camerino 2008
    1. Camerino DC, Desaphy JF, Tricarico D, Pierno S, Liantonio A. Therapeutic approaches to ion channel diseases. Advances in Genetics 2008;64:81-145. - PubMed
Ceccarelli 1992
    1. Ceccarelli M, Rossi B, Siciliano G, Calevro L, Tarantino E. Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine. Acta Paediatrica 1992;81(5):453-5. - PubMed
Charlet 2002
    1. Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Molecular Cell 2002;10(1):45-53. - PubMed
Cleland 2008
    1. Cleland JC, Griggs RC. Treatment of neuromuscular channelopathies: current concepts and future prospects. Neurotherapeutics 2008;5:607-12. - PMC - PubMed
Cürschmann 1912
    1. Cürschmann H. Familial atrophic myotonia [Über famili äre atrophische myotonie]. Deutsche Zeitschrift für Nervenheilkünde 1912;45:161-202.
Dengler 1979
    1. Dengler R, Rudel R. Effects of tocainide on normal and myotonic mammalian skeletal muscle. Arzneimittelforschung 1979;29(2):270-3. - PubMed
Desaphy 2013
    1. Desaphy JF, Madoni A, LoMonaco M, Camerino DC. Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy. European Journal of Clinical Pharmacology 2013;69:1037-9. - PMC - PubMed
Desaphy 2021
    1. Desaphy JF, Altamura C, Vicart S, Fontaine B. Targeted therapies for skeletal muscle ion channelopathies: systematic review and steps towards precision medicine. Journal of Neuromuscular Diseases 2021;8:357-81. - PMC - PubMed
Drost 2001
    1. Drost G, Blok JH, Stegeman DF, Dijk JP, Engelen BG, Zwarts MJ. Propagation disturbance of motor unit action potentials during transient paresis in generalized myotonia: a high density surface EMG study. Brain 2001;124(2):352-60. - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9. - PubMed
Emery 1991
    1. Emery AE. Population frequencies of inherited neuromuscular diseases – a world survey. Neuromuscular Disorders 1991;1(1):19-29. - PubMed
Fontaine 1990
    1. Fontaine B, Khurana TS, Hoffman EP, Bruns GA, Haines JL, Trofatter JA, et al. Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. Science 1990;250(4983):1000-2. - PubMed
Fontaine 1997
    1. Fontaine B, Plassart-Schiess E, Nicole S. Diseases caused by voltage-gated ion channels. Molecular Aspects of Medicine 1997;18(6):415-63. - PubMed
Fowler 1974
    1. Fowler WM Jr, Layzer RB, Taylor RG, Eberle ED, Sims GE, Munsat TL, et al. The Schwartz-Jampel syndrome. Its clinical, physiological and histological expressions. Journal of the Neurological Sciences 1974;22(1):127-46. - PubMed
Franke 1991
    1. Franke C, Laizzo PA, Hatt H, Spittelmeister W, Ricker K, Lehmann-Horn F. Altered Na+ channel activity and reduced Cl- conductance cause hyperexcitability in recessive generalized myotonia (Becker). Muscle & Nerve 1991;14(8):762-70. - PubMed
George 1993
    1. George AL Jr, Crackower MA, Abdalla JA, Hudson AJ, Ebers GC. Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nature Genetics 1993;3(4):305-10. - PubMed
Hammaren 2005
    1. Hammarén E, Kjellby-Wendt G, Lindberg C. Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist. Neuromuscular Disorders 2005;15(9-10):610-7. - PubMed
Harley 1992
    1. Harley HG, Rundle SA, Reardon W, Myring J, Crow S, Brook JD, et al. Unstable DNA sequence in myotonic dystrophy. Lancet 1992;339(8802):1125-8. - PubMed
Harper 2001
    1. Harper PS. Other myotonic disorders and muscular dystrophies: the differential diagnosis of myotonic dystrophy. In: Myotonic Dystrophy. 3rd edition. London (UK): WB Saunders, 2001:47-89.
Harper 2004
    1. Harper PS. Myotonic dystrophy: a multisystemic disorder. In: Harper PS, Engelen B, Eymard B, Wilcox DE, editors(s). Myotonic Dystrophy. New York (NY): Oxford University Press, 2004:3-13.
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from https://training.cochrane.org/handbook/archive/v5.1/.
Higgins 2022
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from https://training.cochrane.org/handbook/archive/v6.3. - PMC - PubMed
Horga 2013
    1. Horga A, Raja Rayan DL, Matthews E, Sud R, Fialho D, Durran SC, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology 2013;80(16):1472-5. - PMC - PubMed
Howeler 1989
    1. Howeler CJ, Busch HF, Geraedts JP, Niermeijer MF, Staal A. Anticipation in myotonic dystrophy: fact or fiction? Brain 1989;112(Pt 3):779-97. - PubMed
Jurkat‐Rott 2001
    1. Jurkat-Rott K, Lehmann-Horn F, Rudel R. Chloride and sodium channel myotonias. In: Rose MR, Griggs RC, editors(s). Channelopathies of the Nervous System. Oxford (UK): Butterworth-Heinemann, 2001.
Koch 1992
    1. Koch MC, Steinmeyer K, Lorenz C, Ricker K, Wolf F, Otto M, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 1992;257(5071):797-800. - PubMed
Leheup 1986
    1. Leheup B, Himon F, Morali A, Brichet F, Vidailhet M. Value of mexiletine in the treatment of Thomsen-Becker myotonia [Interêt de la mexiletine dans le traitement de la myotonie de Thomsen-Becker]. Archives Françaises de Pédiatrie 1986;43(1):49-50. - PubMed
Lehmann‐Horn 1987a
    1. Lehmann-Horn F, Kuther G, Ricker K, Grafe P, Ballanyi K, Rudel R. Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extracellular pH. Muscle & Nerve 1987;10(4):363-74. - PubMed
Lehmann‐Horn 1987b
    1. Lehmann-Horn F, Rudel R, Ricker K. Membrane defects in paramyotonia congenita (Eulenburg). Muscle & Nerve 1987;10(7):633-41. - PubMed
Lehmann‐Horn 1994
    1. Lehmann-Horn F, Engel AG, Ricker K, Rudel R. The periodic paralyses and paramyotonia congenita. In: Engel AG, Franzini-Armstrong C, editors(s). Myology. New York (NY): McGraw-Hill, 1994:1303-34.
Lipicky 1979
    1. Lipicky RJ. Myotonic disorders other than myotonic dystrophy. In: Vinken PJ, Bruyn GW, editors(s). Handbook of Clinical Neurology. Amsterdam (the Netherlands): Elsevier, 1979:533-71.
Logigian 2004
    1. Logigian EL, Moxley RT 4th, Blood CL, Barbieri CA, Martens WB, Wiegner AW, et al. Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1. Neurology 2004;62(7):1081-9. - PubMed
Logigian 2005
    1. Logigian EL, Blood CL, Dilek N, Martens WB, Moxley RT 4th, Wiegner AW, et al. Quantitative analysis of the "warm-up" phenomenon in myotonic dystrophy type 1. Muscle & Nerve 2005;32(1):35-42. - PubMed
Mankodi 2002
    1. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Molecular Cell 2002;10(1):35-44. - PubMed
Markhorst 2014
    1. Markhorst JM, Stunnenberg BC, Ginjaar IB, Drost G, Erasmus CE, Sie LT. Clinical experience with long-term acetazolamide treatment in children with nondystrophic myotonias: a three-case report. Paediatric Neurology 2014;51:537-41. - PubMed
Meola 2000
    1. Meola G, Sansone V. Therapy in myotonic disorders and in muscle channelopathies. Journal of the Neurological Sciences 2000;21(Suppl):953-61. - PubMed
Meola 2004
    1. Meola G, Sansone V. Treatment in myotonia and periodic paralysis. Revue Neurologique 2004;160(5 Pt 2):S55-69. - PubMed
Moxley 1996
    1. Moxley RT 3rd. Proximal myotonic myopathy: mini review of a recently delineated clinical disorder. Neuromuscular Disorders 1996;6(2):87-93. - PubMed
Pouget 1983
    1. Pouget J, Serratrice G. Myotonia with muscular weakness corrected by exercise: the therapeutic effect of mexiletine [Myotonia avec faiblesse musculaire corrigée par l' exercise. Effect therapeutique de la mexiletine]. Revue Neurologique 1983;139(4):665-72. - PubMed
Ptácek 1994
    1. Ptácek LJ, Tawil R, Griggs RC, Meola G, McManis P, Barohn RJ, et al. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita and hyperkalemic periodic paralysis. Neurology 1994;44(8):1500-3. - PubMed
Ptácek 1998
    1. Ptácek LJ. The familial periodic paralyses and nondystrophic myotonias. American Journal of Medicine 1998;105(1):58-70. - PubMed
Ricker 1978
    1. Ricker K, Haass A, Hertel G, Mertens HG. Transient muscular weakness in severe recessive myotonia congenita. Improvement of isometric muscle force by drugs relieving myotomic stiffness. Journal of Neurology 1978;218(4):253-62. - PubMed
Ricker 1999
    1. Ricker K. Myotonic dystrophy and proximal myotonic myopathy. Journal of Neurology 1999;246(5):334-8. - PubMed
Rosenfeld 1997
    1. Rosenfeld J, Sloan-Brown K, George Jr AL. A novel muscle sodium channel mutation causes painful congenital myotonia. Annals of Neurology 1997;42(5):811-4. [DOI: 10.1002/ana.410420520] - DOI - PubMed
Rossi 1985
    1. Rossi B, Siciliano G, Sartucci F. Electrophysiological evaluation of congenital myotonia. Electromyography and Clinical Neurophysiology 1985;25(6):413-22. - PubMed
Rüdel 1994
    1. Rüdel R. Altered excitability of the muscle cell membrane. The non-dystrophic myotonias. In: Engel AG, Franzini-Armstrong C, editors(s). Myology. New York (NY): Mc Graw-Hill, 1994:1291-302.
Sansone 2000
    1. Sansone V, Marinou K, Salvucci J, Meola G. Quantitative myotonia assessment: an experimental protocol. Neurological Sciences 2000;21(5 Suppl):S971-4. - PubMed
Schünemann 2022
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from https://training.cochrane.org/handbook/archive/v6.3.
Shields 1988
    1. Shields AF, Berenson JA. Procainamide-associated pancytopenia. American Journal of Hematology 1988;27(4):299-301. - PubMed
Soff 1987
    1. Soff GA, Kadin ME. Tocainide-induced reversible agranulocytosis and anemia. Archives of Internal Medicine 1987;147(3):598-9. - PubMed
Statland 2011
    1. Statland JM, Wang Y, Richesson R, Bundy B, Herbelin L, Gomes J, et al. An interactive voice response diary for patients with non-dystrophic myotonia. Muscle & Nerve 2011;44(1):30-5. - PMC - PubMed
Steinert 1910
    1. Steinert H. [Ein neuer fall von atrophischer myotonie: ein nachtag zu meiner arbeit in Bild 37]. Deutsche Zeitschrift für Nervenheilkünde 1910;39:168-73.
Sterne 2011
    1. Sterne J, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from https://training.cochrane.org/handbook/archive/v5.1/.
Streib 1986
    1. Streib EW. Successful treatment with tocainide of recessive generalized congenital myotonia. Annals of Neurology 1986;19(5):501-4. - PubMed
Suetterlin 2015
    1. Suetterlin KJ, Bugiardini E, Kaski JP, Morrow JM, Matthews E, Hanna MG, et al. Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies. JAMA Neurology 2015;72(12):1531-3. - PubMed
Terracciano 2018
    1. Terracciano C, Farina O, Esposito T, Lombardi L, Napolitano F, Blasiis PD, et al. Successful long-term therapy with flecainide in a family with paramyotonia congenita. Journal of Neurology, Neurosurgery, and Psychiatry 2018;89(11):1232-4. - PubMed
Thomsen 1876
    1. Thomsen J. [Tonische krampfe in willkurlich beweglichen muskeln in folge von erebter psychischer disposition (Ataxia muscularis?)]. Archiv für Psychiatrie und Nervenkrankheiten 1876;6:702-18.
Trivedi 2013
    1. Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, et al, CINCH Consortium. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain 2013;136(7):2189-200. - PMC - PubMed
Turner 2010
    1. Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. Journal of Neurology, Neurosurgery, and Psychiatry 2010;81(4):358-67. - PubMed
Vivekanandam 2020a
    1. Vivekanandam V, Minut P, Hanna MG, Matthews E. Skeletal muscle channelopathies. Neurologic Clinics 2020;38(3):481-91. - PubMed
Vivekanandam 2020b
    1. Vivekanandam V, Mannikko R, Matthews E, Hanna MG. Improving genetic diagnostics of skeletal muscle channelopathies. Expert Review of Molecular Diagnostics 2020;20(7):725-36. - PubMed
Vivekanandam 2023
    1. Vivekanandam V, Jaibaji R, Sud R, Ellmers R, Skorupinska I, Germaine L, et al. Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing. Neuromuscular Disorders 2023;33(3):270-3. - PubMed
Vivekanandam 2024
    1. Vivekanandam V, Skorupinska I, Jayaseelan D, Matthews E, Barohn RJ, McDermott MP, et al. Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial. Lancet Neurology 2024;23:1004-12. - PubMed
Wolf 1936
    1. Wolf A. Quinine: an effective form of treatment of myotonia. Archives of Neurology and Psychiatry 1936;36:382-4.

References to other published versions of this review

Trip 2004
    1. Trip J, Engelen BB, Drost GG, Faber CG, Faber KC. Drug treatment for myotonia. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No: CD004762. [DOI: 10.1002/14651858.CD004762] - DOI - PMC - PubMed
Trip 2006
    1. Trip J, Drost GG, Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No: CD004762. [DOI: 10.1002/14651858.CD004762.pub2] - DOI - PMC - PubMed

Substances

Associated data

LinkOut - more resources